Literature DB >> 33478507

Factors associated with access and adherence to artemisinin-based combination therapy (ACT) for children under five: a secondary analysis of a national survey in Sierra Leone.

Kristin Banek1,2, Emily L Webb3, Emily Bostick Doogue4, Samuel Juana Smith5, Daniel Chandramohan6, Sarah G Staedke7.   

Abstract

BACKGROUND: Access and adherence to artemisinin-based combination therapy (ACT) are key challenges to effective malaria treatment. A secondary analysis of the Sierra Leone malaria Knowledge, Attitudes, and Practices (mKAP) survey was conducted to investigate access and adherence to ACT for the treatment of fever in children under-five.
METHODS: The mKAP was a nationally representative, two-stage cluster-sample survey, conducted in 2012. Thirty primary sampling units per district were randomly selected using probability proportionate to size, based on national census estimates; 14 households were subsequently randomly selected and enrolled per sampling unit. The analysis was restricted to children under-five with fever in the past two weeks. Factors associated with access and adherence were assessed using multivariate logistic regression.
RESULTS: Of 5169 enrolled households, 1456 reported at least one child under-five with fever in the past two weeks. Of the 1641 children from these households, 982 (59.8%) received any treatment for fever and were analysed for access to ACT; 469 (47.6%) received ACT and 466 were analysed for treatment adherence. Only 222 (47.4%) febrile children received ACT and completed 3-day treatment. In an adjusted analysis, factors associated with ACT access included knowledge of ACT (odds ratio [OR] 2.78, 95% CI 2.02-3.80; p < 0.001), knowledge of insecticide-treated nets (ITNs) (OR 1.84, 95% CI 1.29-2.63; p = 0.001), source of care (public health facility vs. other; OR 1.86, 95% CI 1.27-2.72, p = 0.001), geographic region (East vs. West; OR 2.30, 95% CI 1.20-4.44; p = 0.025), and age (24-59 vs. 0-23 months; OR 1.45, 95% CI 1.07-1.96; p = 0.016). The only factor associated with ACT adherence was time to treatment; children treated within 24 h were less likely to adhere (OR 0.55, 95% CI 0.34-0.89; p = 0.015).
CONCLUSIONS: In 2012, access and adherence to ACT remained low in Sierra Leone. Knowledge of ACT and ITNs, and seeking care in the public sector, were most strongly associated with ACT access. National surveys provide important information on anti-malarial access and could be expanded to measure treatment adherence.

Entities:  

Keywords:  Access; Adherence; Antimalarial; Artemisinin-based combination therapy (ACT); Malaria; Prompt treatment; Sierra Leone; Treatment completion

Mesh:

Substances:

Year:  2021        PMID: 33478507      PMCID: PMC7817959          DOI: 10.1186/s12936-021-03590-9

Source DB:  PubMed          Journal:  Malar J        ISSN: 1475-2875            Impact factor:   2.979


  25 in total

1.  Rethinking adherence.

Authors:  John F Steiner
Journal:  Ann Intern Med       Date:  2012-10-16       Impact factor: 25.391

2.  The free healthcare initiative in Sierra Leone: Evaluating a health system reform, 2010-2015.

Authors:  Sophie Witter; Nouria Brikci; Tim Harris; Richard Williams; Sarah Keen; Ana Mujica; Alex Jones; Alex Murray-Zmijewski; Barbara Bale; Bailah Leigh; Ade Renner
Journal:  Int J Health Plann Manage       Date:  2018-01-12

3.  Knockdown and recovery of malaria diagnosis and treatment in Liberia during and after the 2014 Ebola outbreak.

Authors:  N K Dunbar; E E Richards; D Woldeyohannes; R Van den Bergh; E Wilkinson; D Tamang; P Owiti
Journal:  Public Health Action       Date:  2017-06-21

4.  Barriers to prompt and effective malaria treatment among the poorest population in Kenya.

Authors:  Jane Chuma; Vincent Okungu; Catherine Molyneux
Journal:  Malar J       Date:  2010-05-27       Impact factor: 2.979

5.  Who gets prompt access to artemisinin-based combination therapy? A prospective community-based study in children from rural Kilosa, Tanzania.

Authors:  Daudi O Simba; Marian Warsame; Deodatus Kakoko; Zakayo Mrango; Goran Tomson; Zul Premji; Max Petzold
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

Review 6.  A research agenda for malaria eradication: health systems and operational research.

Authors: 
Journal:  PLoS Med       Date:  2011-01-25       Impact factor: 11.069

7.  Knowledge and behaviour as determinants of anti-malarial drug use in a peri-urban population from malaria holoendemic region of western Kenya.

Authors:  Carren A Watsierah; Walter G Z O Jura; Evans Raballah; Dan Kaseje; Benard Abong'o; Collins Ouma
Journal:  Malar J       Date:  2011-04-20       Impact factor: 2.979

8.  Patient adherence to prescribed artemisinin-based combination therapy in Garissa County, Kenya, after three years of health care in a conflict setting.

Authors:  Georgia R Gore-Langton; Nfornuh Alenwi; James Mungai; Nahashon I Erupe; Katie Eves; Francis Njoroge Kimwana; David Soti; Willis Akhwale; Farah A Hassan; Elizabeth Juma; Richard Allan
Journal:  Malar J       Date:  2015-03-24       Impact factor: 2.979

9.  Impact of Ebola outbreak on reproductive health services in a rural district of Sierra Leone: a prospective observational study.

Authors:  Gianluca Quaglio; Francesca Tognon; Livio Finos; David Bome; Santigie Sesay; Atiba Kebbie; Francesco Di Gennaro; Bienvenu Salim Camara; Claudia Marotta; Vincenzo Pisani; Zainab Bangura; Damiano Pizzol; Annalisa Saracino; Walter Mazzucco; Susan Jones; Giovanni Putoto
Journal:  BMJ Open       Date:  2019-09-04       Impact factor: 2.692

10.  High adherence to antimalarials and antibiotics under integrated community case management of illness in children less than five years in eastern Uganda.

Authors:  Joan N Kalyango; Elizeus Rutebemberwa; Charles Karamagi; Edison Mworozi; Sarah Ssali; Tobias Alfven; Stefan Peterson
Journal:  PLoS One       Date:  2013-03-29       Impact factor: 3.240

View more
  1 in total

1.  Evaluating recurrent episodes of malaria incidence in Timika, Indonesia, through a Markovian multiple-state model.

Authors:  Novyan Lusiyana; Atina Ahdika
Journal:  Infect Dis Model       Date:  2022-06-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.